Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...
AstraZeneca plans $1.5 billion ADC manufacturing facility in Singapore, boosting global supply of cancer treatments. Learn more about this greenfield investment...
AstraZeneca's sipavibart shows promising results in Phase III COVID-19 prevention trial for immunocompromised patients, reducing symptomatic cases significantly. A potential game-changer in protecting vulnerable populations...
AstraZeneca plc (LON:AZN) completes equity investment with Cellectis, aiming to develop innovative cell and gene therapy products for various medical needs...
AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...
AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment...
AstraZeneca's Imfinzi shows significant improvement in overall survival and progression-free survival in limited-stage small cell lung cancer patients after chemoradiotherapy. Exciting breakthrough in treatment...
Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...
AstraZeneca plans $1.5 billion ADC manufacturing facility in Singapore, boosting global supply of cancer treatments. Learn more about this greenfield investment...
AstraZeneca's sipavibart shows promising results in Phase III COVID-19 prevention trial for immunocompromised patients, reducing symptomatic cases significantly. A potential game-changer in protecting vulnerable populations...
AstraZeneca plc (LON:AZN) completes equity investment with Cellectis, aiming to develop innovative cell and gene therapy products for various medical needs...
AstraZeneca plc (LON:AZN) announces a 7% increase in annual dividend for 2024 to $3.10 per share, reflecting confidence in performance and cash generation...
AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment...
AstraZeneca's Imfinzi shows significant improvement in overall survival and progression-free survival in limited-stage small cell lung cancer patients after chemoradiotherapy. Exciting breakthrough in treatment...
